TG Therapeutics, Inc.
Commercial B-cell-focused biotech led by BRIUMVI for relapsing multiple sclerosis, with lifecycle and autoimmune expansion programs.
Neurology / autoimmune disease · Anti-CD20 monoclonal antibodies & cellular therapy · Commercial + Phase 3